Rigel Pharmaceuticals
RIGL
100 hedge funds and large institutions have $227M invested in Rigel Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 30 reducing their positions, and 12 closing their positions.
52% more call options, than puts
Call options by funds: $444K | Put options by funds: $293K
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
17% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 30
5% more funds holding
Funds holding: 95 → 100 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
24% less capital invested
Capital invested by funds: $300M → $227M (-$73.5M)
Top Buyers
| 1 |
VAM
Visium Asset Management
New York
|
+$5.9M |
| 2 |
BC
Broadfin Capital
New York
|
+$4.08M |
| 3 |
Renaissance Technologies
New York
|
+$2.04M |
| 4 |
Two Sigma Investments
New York
|
+$1.81M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.66M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.5M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$5.25M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.82M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$3.18M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FM
101
Forward Management
San Francisco,
California
| – | -$1.35M | -41,520 | Closed |
|
102
TD Asset Management
Toronto,
Ontario, Canada
| – | -$279K | -7,780 | Closed |
|
|
PIM
103
Platinum Investment Management
Sydney Australia 2000,
Australia
| – | -$240K | -6,730 | Closed |
|
104
Allianz Asset Management
Munich,
Germany
| – | -$97K | -2,700 | Closed |
|
|
OC
105
Oppenheimer & Co
New York
| – | -$72K | -2,000 | Closed |
|
106
SG Americas Securities
New York
| – | -$56K | -1,557 | Closed |
|
|
FSA
107
Franklin Street Advisors
Chapel Hill,
North Carolina
| – | -$49K | -1,350 | Closed |
|
|
ST
108
Spot Trading
Chicago,
Illinois
| – | -$48K | -1,328 | Closed |
|
109
Ameriprise
Minneapolis,
Minnesota
| – | -$19K | -543 | Closed |
|
110
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$5K | -138 | Closed |
|
|
EFSCE
111
Enterprise Financial Services Corp (EFSC)
Clayton,
Missouri
| – | -$1K | -40 | Closed |
|
RIGL Hedge Fund Activity: Q4 2013 in Review
100 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2013, worth a combined $227M — down 24% from $300M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new RIGL positions and 12 closed out — a net gain of 5 holders — while 35 added to existing stakes and 30 trimmed.
The largest buyer was Visium Asset Management, opening a new position worth an estimated $5.9M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $16.5M sold.
- 100 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2013, up from 95 in Q3 2013.
- Funds reported $227M of Rigel Pharmaceuticals stock for Q4 2013, down 24% quarter-over-quarter.
- 17 funds opened new Rigel Pharmaceuticals positions in Q4 2013 and 12 closed out, a net change of +5 holders.
- The largest Rigel Pharmaceuticals buyer in Q4 2013 was Visium Asset Management, an estimated $5.9M added.
- The largest Rigel Pharmaceuticals seller in Q4 2013 was T. Rowe Price Associates, an estimated $16.5M sold.
Based on aggregated 13F filings for Q4 2013.